Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Neratinib
CHF 96.00
In stock
SYN-1140-M0011 mgCHF 96.00
SYN-1140-M0055 mgCHF 144.00
SYN-1140-M01010 mgCHF 251.00
SYN-1140-M05050 mgCHF 856.00
SYN-1140-M100100 mgCHF 1'257.00
| Product Details | |
|---|---|
| Synonyms | HKI-272 |
| Product Type | Chemical |
| Properties | |
| Formula | C30H29ClN6O3 |
| MW | 557.0 |
| CAS | 698387-09-6 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: EGFR | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | JWNPDZNEKVCWMY-VQHVLOKHSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Neratinib (HKI-272) is an orally available, irreversible tyrosine kinase inhibitor with IC(50) values of 59nM and 92nM for HER2 and EGFR, respectively. It is in development for the treatment of early- and late-stage HER2-positive breast cancer.
Product References
- Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase: S.K. Rabindran, et al.; Cancer Res. 64, 3958 (2004)
Related Products
